Kongmeng

Kongmeng Biopharma is a biotechnology company focused on the development of targeted protein degradation (TPD) therapies, with a specific emphasis on molecular glue degraders. The company utilizes a proprietary discovery platform to identify small molecules that can induce the degradation of disease-causing proteins that were previously considered undruggable. Their lead research programs are directed toward oncology, targeting proteins such as GSPT1 to treat various cancers. Based in Shanghai, Kongmeng Biopharma aims to advance its pipeline into clinical trials to address significant unmet medical needs in the field of hematology and solid tumors.